Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Syros price target lowered to $14 from $18 at Alliance Global Partners » 12:19
03/05/21
03/05
12:19
03/05/21
12:19
SYRS

Syros Pharmaceuticals

$7.18 /

-0.75 (-9.46%)

Alliance Global Partners…

Alliance Global Partners analyst Matt Cross lowered the firm's price target on Syros Pharmaceuticals to $14 from $18 and keeps a Buy rating on the shares. The subsequent Phase 2 trial of SY-1425 pushes back the analyst's expected timeframe for a U.S. launch in acute myelogenous leukemia to 2026. The AML landscape is "rapidly shifting" and Syros will need to "remain nimble" as it looks to combine SY-1425 with other therapeutics in this setting, Cross tells investors in a research note.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$7.18 /

-0.75 (-9.46%)

SYRS Syros Pharmaceuticals
$7.18 /

-0.75 (-9.46%)

11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
11/04/20
Fly Intel: Top five analyst upgrades
11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
SYRS Syros Pharmaceuticals
$7.18 /

-0.75 (-9.46%)

  • 20
    Jan
SYRS Syros Pharmaceuticals
$7.18 /

-0.75 (-9.46%)

Thursday
Earnings
Syros Pharmaceuticals reports Q4 EPS (62c), consensus (50c) » 07:33
03/04/21
03/04
07:33
03/04/21
07:33
SYRS

Syros Pharmaceuticals

$8.33 /

-0.87 (-9.46%)

Reports Q4 revenue $5.7M,…

Reports Q4 revenue $5.7M, consensus $2.7M. Cash, cash equivalents and marketable securities as of December 31, 2020 were $174M, as compared with $91.4M on December 31, 2019. "2021 promises to be a pivotal year for Syros," said Nancy Simonian, CEO of Syros. "We moved our lead program into our first registration-enabling study and continue to advance all three of our clinical-stage programs with the aim of setting new standards of care for targeted populations of patients with hematological malignancies and solid tumors. Following our recent financings, we are operating from a position of substantial strength, with capital to advance SY-1425, SY-2101 and SY-5609 through multiple expected data readouts while investing in our gene control platform to fuel our long-term pipeline. We are focused on executing with excellence as we accelerate toward our goal of bringing medicines to market that provide profound benefits for patients."

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$8.33 /

-0.87 (-9.46%)

SYRS Syros Pharmaceuticals
$8.33 /

-0.87 (-9.46%)

11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
11/04/20
Fly Intel: Top five analyst upgrades
11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
SYRS Syros Pharmaceuticals
$8.33 /

-0.87 (-9.46%)

  • 20
    Jan
SYRS Syros Pharmaceuticals
$8.33 /

-0.87 (-9.46%)

Upgrade
J.B. Hunt upgraded to Buy on 'robust' demand at BofA » 07:08
03/04/21
03/04
07:08
03/04/21
07:08
JBHT

J.B. Hunt

$152.57 /

+1.7 (+1.13%)

As previously reported,…

As previously reported, BofA analyst Ken Hoexter upgraded J.B. Hunt to Buy from Neutral with a price target of $171, up from $151, as part of his upgrade of a number of truckload and intermodal stocks. While he has lowered his Q1 estimates for the group to account for February's winter storms, he generally is lifting his 2021 and 2022 estimates to reflect improved pricing and demand. With inventory replenishment set to continue through the summer, and consumer demand remaining high, Hoexter sees truckload carriers being positioned to "capitalize on a robust 2021 demand environment," he tells investors.

ShowHide Related Items >><<
JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

03/04/21 BofA
J.B. Hunt upgraded to Buy from Neutral at BofA
01/26/21 Susquehanna
J.B. Hunt downgraded to Neutral from Positive at Susquehanna
01/26/21 Susquehanna
J.B. Hunt downgraded to Neutral from Positive at Susquehanna
01/21/21 Deutsche Bank
J.B. Hunt price target raised to $146 from $139 at Deutsche Bank
JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

Upgrade
J.B. Hunt upgraded to Buy from Neutral at BofA » 06:58
03/04/21
03/04
06:58
03/04/21
06:58
JBHT

J.B. Hunt

$152.57 /

+1.7 (+1.13%)

BofA analyst Ken Hoexter…

BofA analyst Ken Hoexter upgraded J.B. Hunt to Buy from Neutral with a price target of $171, up from $151.

ShowHide Related Items >><<
JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

01/26/21 Susquehanna
J.B. Hunt downgraded to Neutral from Positive at Susquehanna
01/26/21 Susquehanna
J.B. Hunt downgraded to Neutral from Positive at Susquehanna
01/21/21 Deutsche Bank
J.B. Hunt price target raised to $146 from $139 at Deutsche Bank
01/20/21 JPMorgan
J.B. Hunt shares will 'lag the group,' says JPMorgan
JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

JBHT J.B. Hunt
$152.57 /

+1.7 (+1.13%)

Wednesday
On The Fly
#SocialStocks: Facebook resumes political ads, Twitter announces long-term goals » 15:09
03/03/21
03/03
15:09
03/03/21
15:09
FB

Facebook

$257.05 /

-1.76 (-0.68%)

, TWTR

Twitter

$71.81 /

-1.84 (-2.50%)

, NFLX

Netflix

$523.83 /

-23.85 (-4.35%)

, WMT

Walmart

$128.50 /

-1.59 (-1.22%)

, ORCL

Oracle

$66.98 /

+0.31 (+0.46%)

, SNAP

Snap

$61.05 /

-3.44 (-5.33%)

Welcome to…

ShowHide Related Items >><<
WMT Walmart
$128.50 /

-1.59 (-1.22%)

TWTR Twitter
$71.81 /

-1.84 (-2.50%)

SNAP Snap
$61.05 /

-3.44 (-5.33%)

ORCL Oracle
$66.98 /

+0.31 (+0.46%)

NFLX Netflix
$523.83 /

-23.85 (-4.35%)

FB Facebook
$257.05 /

-1.76 (-0.68%)

FB Facebook
$257.05 /

-1.76 (-0.68%)

02/26/21 Jefferies
Twitter price target raised to $79 from $64 at Jefferies
02/16/21 Loop Capital
Facebook price target raised to $370 from $330 at Loop Capital
02/10/21 Tigress Financial
Facebook has 'significant upside' at current levels, says Tigress
02/01/21 Truist
Alphabet price target raised to $2,100 from $2,000 at Truist
TWTR Twitter
$71.81 /

-1.84 (-2.50%)

03/01/21
Fly Intel: Top five analyst upgrades
03/01/21 Cleveland Research
Twitter upgraded to Buy on improved 2021 outlook at Cleveland Research
03/01/21 Cleveland Research
Twitter upgraded to Buy from Neutral at Cleveland Research
02/26/21 Stifel
Twitter price target raised to $70 from $60 at Stifel
NFLX Netflix
$523.83 /

-23.85 (-4.35%)

02/25/21 Needham
ViacomCBS price target raised to $80 from $55 at Needham
02/17/21 Morgan Stanley
Roku price target raised to $275 from $200 at Morgan Stanley
02/16/21 Argus
Mattel upgraded to Buy from Hold at Argus
01/22/21 UBS
Disney upgraded to Buy from Neutral at UBS
WMT Walmart
$128.50 /

-1.59 (-1.22%)

02/23/21 Evercore ISI
Walmart accelerating change with investments, says Evercore ISI
02/19/21 Morgan Stanley
Walmart terminal value rising with investments, says Morgan Stanley
02/19/21 Cowen
Walmart weakness a buying opportunity, says Cowen
02/19/21 Deutsche Bank
Walmart price target lowered to $166 from $170 at Deutsche Bank
ORCL Oracle
$66.98 /

+0.31 (+0.46%)

03/03/21 Citi
Oracle assumed with a Neutral at Citi
02/17/21 BMO Capital
Cornerstone OnDemand price target raised to $63 from $47 at BMO Capital
01/21/21 Goldman Sachs
Oracle initiated with a Sell at Goldman Sachs
12/18/20
Fly Intel: Top five analyst upgrades
SNAP Snap
$61.05 /

-3.44 (-5.33%)

02/24/21 Evercore ISI
Snap price target raised to $75 from $57 at Evercore ISI
02/24/21 Cowen
Snap price target raised to $86 from $70 at Cowen
02/24/21 Credit Suisse
Snap price target raised to $80 from $65 at Credit Suisse
02/24/21 KeyBanc
Snap price target raised to $87 from $63 at KeyBanc
WMT Walmart
$128.50 /

-1.59 (-1.22%)

TWTR Twitter
$71.81 /

-1.84 (-2.50%)

SNAP Snap
$61.05 /

-3.44 (-5.33%)

ORCL Oracle
$66.98 /

+0.31 (+0.46%)

NFLX Netflix
$523.83 /

-23.85 (-4.35%)

FB Facebook
$257.05 /

-1.76 (-0.68%)

WMT Walmart
$128.50 /

-1.59 (-1.22%)

TWTR Twitter
$71.81 /

-1.84 (-2.50%)

SNAP Snap
$61.05 /

-3.44 (-5.33%)

ORCL Oracle
$66.98 /

+0.31 (+0.46%)

NFLX Netflix
$523.83 /

-23.85 (-4.35%)

FB Facebook
$257.05 /

-1.76 (-0.68%)

WMT Walmart
$128.50 /

-1.59 (-1.22%)

TWTR Twitter
$71.81 /

-1.84 (-2.50%)

SNAP Snap
$61.05 /

-3.44 (-5.33%)

ORCL Oracle
$66.98 /

+0.31 (+0.46%)

NFLX Netflix
$523.83 /

-23.85 (-4.35%)

FB Facebook
$257.05 /

-1.76 (-0.68%)

WMT Walmart
$128.50 /

-1.59 (-1.22%)

TWTR Twitter
$71.81 /

-1.84 (-2.50%)

SNAP Snap
$61.05 /

-3.44 (-5.33%)

ORCL Oracle
$66.98 /

+0.31 (+0.46%)

NFLX Netflix
$523.83 /

-23.85 (-4.35%)

FB Facebook
$257.05 /

-1.76 (-0.68%)

Hot Stocks
Netflix launches Fast Laughs feature for mobile devices » 12:50
03/03/21
03/03
12:50
03/03/21
12:50
NFLX

Netflix

$527.98 /

-19.7 (-3.60%)

Netflix said it is…

Netflix said it is launching a new Fast Laughs feature for mobile devices. "Fast Laughs offers a full-screen feed of funny clips from our big comedy catalog including films (Murder Mystery), series (Big Mouth), sitcoms (The Crew) and stand-up from comedians like Kevin Hart and Ali Wong," the company said. "You access the feed through your bottom navigation menu by clicking on the Fast Laughs tab. Clips will start playing - when one ends another begins, to keep the laughs coming." Fast Laughs is available now for iPhone users in select countries, and Netflix will be testing the feature on Android soon. Reference Link

ShowHide Related Items >><<
NFLX Netflix
$527.98 /

-19.7 (-3.60%)

NFLX Netflix
$527.98 /

-19.7 (-3.60%)

02/25/21 Needham
ViacomCBS price target raised to $80 from $55 at Needham
02/17/21 Morgan Stanley
Roku price target raised to $275 from $200 at Morgan Stanley
02/16/21 Argus
Mattel upgraded to Buy from Hold at Argus
01/22/21 UBS
Disney upgraded to Buy from Neutral at UBS
NFLX Netflix
$527.98 /

-19.7 (-3.60%)

NFLX Netflix
$527.98 /

-19.7 (-3.60%)

NFLX Netflix
$527.98 /

-19.7 (-3.60%)

NFLX Netflix
$527.98 /

-19.7 (-3.60%)

Recommendations
Lithium Americas price target lowered to C$30.50 from C$31 at Canaccord » 11:52
03/03/21
03/03
11:52
03/03/21
11:52
LAC

Lithium Americas

$17.91 /

-0.98 (-5.19%)

Canaccord analyst Katie…

Canaccord analyst Katie Lachapelle lowered the firm's price target on Lithium Americas to C$30.50 from C$31 and keeps a Speculative Buy rating on the shares.

ShowHide Related Items >><<
LAC Lithium Americas
$17.91 /

-0.98 (-5.19%)

LAC Lithium Americas
$17.91 /

-0.98 (-5.19%)

02/02/21 National Bank
Lithium Americas price target raised to $23 from $20 at National Bank
01/21/21 BMO Capital
Lithium Americas price target raised to C$20 from C$13 at BMO Capital
01/21/21 BMO Capital
Lithium Americas price target raised to C$20 from C$13 at BMO Capital
01/06/21 Canaccord
Lithium Americas price target raised to C$20 from C$11.50 at Canaccord
  • 20
    Jan
LAC Lithium Americas
$17.91 /

-0.98 (-5.19%)

LAC Lithium Americas
$17.91 /

-0.98 (-5.19%)

Hot Stocks
Bionano Genomics customer Praxis Genomics receives DEX Z-codes from Palmetto » 09:30
03/03/21
03/03
09:30
03/03/21
09:30
BNGO

Bionano Genomics

$9.47 /

-0.37 (-3.76%)

Bionano Genomics…

Bionano Genomics announced that Praxis Genomics, LLC received DEX Z-codes from Palmetto MolDX for its entire testing menu of laboratory developed tests based on Saphyr. The DEX Z-Code modifier is a unique 5-character alpha-numeric code associated with certain molecular diagnostics tests and is typically used by certain payers as an adjunct to non-specific CPT codes when no specific CPT code applies. The code, submitted on a claim along with a particular CPT code provides greater clarity to help payers and physicians understand which test is being ordered, performed and billed. The process removes the need for the provider to submit large amounts of additional information with every claim and can expedite claim payment. The assignment of DEX Z-codes to Praxis's menu of Saphyr-based LDTs is potentially a major step forward in the coding and eventual coverage of Saphyr-based tests. Praxis is the first CAP-accredited, CLIA-certified diagnostic lab in the United States to develop and offer commercially an LDT based on whole genome analysis with Saphyr. Praxis uses optical genome mapping as an alternative to traditional methods of chromosomal microarray and karyotyping, as they seek to improve the rate of clinical diagnosis for patients with genetic disease. The Z-codes allow for a path for Medicare coverage and private insurance reimbursement for OGM with Saphyr of patients with suspected genetic disease.

ShowHide Related Items >><<
BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

  • 20
    Jan
  • 08
    Jan
BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

Recommendations
Perion Network price target raised to $31 after guidance hike at Lake Street » 09:07
03/03/21
03/03
09:07
03/03/21
09:07
PERI

Perion Network

$25.64 /

+4.135 (+19.23%)

Lake Street analyst Eric…

Lake Street analyst Eric Martinuzzi raised the firm's price target on Perion Network (PERI) to $31 from $30 and keeps a Buy rating on the shares after the company raised both its Q1 and 2021 guidance for revenue and AEBITDA ahead of its March 8 investor day meeting. Search advertising spending has remained healthy early in 2021 and one of the benefits of Perion's 2020 contract renewal with Microsoft (MSFT) was an increased ability to monetize the relationship, said Martinuzzi, who adds that Perion's "outperformance remains impressive."

ShowHide Related Items >><<
PERI Perion Network
$25.64 /

+4.135 (+19.23%)

PERI Perion Network
$25.64 /

+4.135 (+19.23%)

02/10/21 Lake Street
Perion Network price target raised to $30 from $18 at Lake Street
02/10/21 Roth Capital
Perion Network price target raised to $30 from $16 at Roth Capital
01/04/21 Lake Street
Perion Network price target raised to $18 from $12 at Lake Street
12/31/20 Sidoti
Perion Network price target raised to $14 from $12 at Sidoti
PERI Perion Network
$25.64 /

+4.135 (+19.23%)

  • 20
    Jan
PERI Perion Network
$25.64 /

+4.135 (+19.23%)

Conference/Events
The Genome Partnership to hold a virtual meeting » 04:55
03/03/21
03/03
04:55
03/03/21
04:55
NSTG

NanoString

$74.34 /

-0.15 (-0.20%)

, TWST

Twist Bioscience

$141.72 /

-3.31 (-2.28%)

, PACB

Pacific Biosciences

$34.32 /

-0.925 (-2.62%)

, QGEN

Qiagen

$50.49 /

+0.14 (+0.28%)

, TXG

10x Genomics

$186.77 /

-0.02 (-0.01%)

, CDXS

Codexis

$22.59 /

-0.81 (-3.46%)

, PKI

PerkinElmer

$127.46 /

-2.31 (-1.78%)

, ILMN

Illumina

$441.51 /

-4.8 (-1.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BNGO

Bionano Genomics

$9.47 /

-0.37 (-3.76%)

Advances in Genome…

Advances in Genome Biology & Technology: AGBT 2021 Virtual Meeting will be held on March 1-3. Webcast Link

ShowHide Related Items >><<
TXG 10x Genomics
$186.77 /

-0.02 (-0.01%)

TWST Twist Bioscience
$141.72 /

-3.31 (-2.28%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

NSTG NanoString
$74.34 /

-0.15 (-0.20%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

CDXS Codexis
$22.59 /

-0.81 (-3.46%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

NSTG NanoString
$74.34 /

-0.15 (-0.20%)

03/02/21 JPMorgan
NanoString price target raised to $80 from $75 at JPMorgan
03/02/21 Baird
NanoString price target raised to $78 from $70 at Baird
01/11/21 Baird
NanoString price target raised to $70 from $60 at Baird
01/06/21 Cowen
NanoString upgraded to Outperform with $75 target at Cowen
TWST Twist Bioscience
$141.72 /

-3.31 (-2.28%)

02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
02/05/21 JPMorgan
Twist Bioscience downgraded to Underweight from Neutral at JPMorgan
01/04/21 Evercore ISI
Evercore ISI cuts Twist Bioscience to In Line, says new verticals take time
01/04/21 Evercore ISI
Twist Bioscience downgraded to In Line from Outperform at Evercore ISI
PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

02/11/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $62 from $45 at Cantor Fitzgerald
02/11/21 Piper Sandler
Pacific Biosciences upgraded to Overweight from Neutral at Piper Sandler
01/15/21 Piper Sandler
Pacific Biosciences price target raised to $20 from $12 at Piper Sandler
01/12/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $45 from $25 at Cantor Fitzgerald
QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
TXG 10x Genomics
$186.77 /

-0.02 (-0.01%)

02/18/21 Cowen
10x Genomics price target raised to $200 from $155 at Cowen
02/18/21 JPMorgan
10x Genomics price target raised to $195 from $160 at JPMorgan
02/18/21 Citi
10x Genomics price target raised to $240 from $195 at Citi
12/16/20 Citi
10x Genomics price target raised to $195 from $165 at Citi
CDXS Codexis
$22.59 /

-0.81 (-3.46%)

03/01/21 Stifel
Codexis initiated with a Buy at Stifel
12/30/20 Benchmark
Codexis price target raised to $29 from $21 at Benchmark
07/15/20 Stephens
Codexis resumed with an Overweight at Stephens
03/10/20 Benchmark
Codexis initiated with a Buy at Benchmark
PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
ILMN Illumina
$441.51 /

-4.8 (-1.08%)

03/02/21 Barclays
Illumina started with an Underweight at Barclays on near-term growth issues
03/02/21 Barclays
Illumina initiated with an Underweight at Barclays
02/16/21 BTIG
Illumina price target raised to $570 from $410 at BTIG
02/12/21 Piper Sandler
Illumina price target raised to $510 from $415 at Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

02/25/21 Berenberg
Roche price target lowered to CHF 320 from CHF 325 at Berenberg
02/24/21 Morgan Stanley
Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/17/21 UBS
UBS downgrades Roche to Neutral on risk to 2022 estimates
BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
TXG 10x Genomics
$186.77 /

-0.02 (-0.01%)

TWST Twist Bioscience
$141.72 /

-3.31 (-2.28%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

NSTG NanoString
$74.34 /

-0.15 (-0.20%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

CDXS Codexis
$22.59 /

-0.81 (-3.46%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

  • 20
    Jan
  • 08
    Jan
  • 03
    Dec
  • 03
    Dec
  • 11
    Nov
  • 08
    Oct
  • 11
    Sep
  • 12
    Aug
  • 04
    Jun
RHHBY Roche
$0.00 /

+ (+0.00%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

TXG 10x Genomics
$186.77 /

-0.02 (-0.01%)

TWST Twist Bioscience
$141.72 /

-3.31 (-2.28%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

NSTG NanoString
$74.34 /

-0.15 (-0.20%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

CDXS Codexis
$22.59 /

-0.81 (-3.46%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.